Cardio Poll: How will the SMART DATE study results impact your clinical practice?
How do you think novel evidence from this late breaking trial presented at ACC.18 will impact clinical practice? Compare your answers with those of the PCRonline community!
The recent SMART-DATE trial ultimately showed non-inferiority for MACE of 6 months vs. 12 months DAPT in ACS patients treated with current generation DES. Yet, myocardial infarction (a secondary endpoint) was increased by 1% in the short DAPT group and no difference for stent thrombosis and major bleeding was observed between the two treatment arms.
More about this trial:
- No. of participants: 2,700 patients
- Follow-up: 18 months
- Primary endpoint: non-inferiority for all-cause death, myocardial infarction, and cerebrovascular events